Dataset Information


Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

ABSTRACT: P-glycoprotein limits the tissue penetration of many antiretroviral drugs. The aim of our study was to characterize the effects of the P-glycoprotein substrate cyclosporin A on T cell P-glycoprotein activity in human immunodeficiency virus-infected participants in the AIDS Clinical Trials Group study A5138.We studied P-glycoprotein activity on CD4 and CD8 T cells in 16 participants randomized to receive oral cyclosporin A (n=9) or not (n=7) during initiation antiretroviral therapy (ART) that did not include protease or non-nucleoside reverse transcriptase inhibitors.CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001). Plasma trough cyclosporin A concentrations correlated with the change in P-glycoprotein activity in several T cell subsets.Oral cyclosporin A can inhibit peripheral blood CD4 T cell P-glycoprotein activity. Targeted P-glycoprotein inhibition may enhance the delivery of ART to T cells.

PROVIDER: S-EPMC2873632 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4808326 | BioStudies
| S-EPMC5319792 | BioStudies
2001-01-01 | S-EPMC1221690 | BioStudies
| S-EPMC6467559 | BioStudies
| S-EPMC8460250 | BioStudies
| S-EPMC7159248 | BioStudies
| S-EPMC3923537 | BioStudies
| S-EPMC5707537 | BioStudies
| S-EPMC2715775 | BioStudies
| S-EPMC4371767 | BioStudies